Core Viewpoint - Dagan Holdings (300103.SZ) expects a net profit attributable to shareholders of the listed company for 2025 to be between -71 million yuan and -50 million yuan, indicating a significant reduction in losses compared to previous periods [1] Financial Performance - The company anticipates a net profit, excluding non-recurring gains and losses, to be between -72.06 million yuan and -51.06 million yuan for 2025 [1] - The adjustment in business strategy based on market demand and the development of various business segments has contributed to a substantial reduction in overall losses [1] Accounting and Provisions - The company plans to recognize credit impairment provisions for receivables and inventory write-downs in accordance with accounting standards and policies, reflecting a cautious approach to its financial reporting [1] - The impairment testing is still ongoing, and the final impairment amounts will be disclosed in the audited 2025 annual report [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 （1）经财务部门初步测算，预计2025年年度实现归属于母公司所有者的净利润将出现亏损，实现归属 于母公司所有者的净利润-11,000万元到-15,000万元。 （2）归属于母公司所有者扣除非经常性损益后的净利润 -13,000万元到 -19,000万元。 （二）每股收益：-0.87元。 三、本期业绩变化的主要原因 2025年，部分客户基于因自身终端销售预期及供应链情况调整了采购节奏，阶段性放缓了提货节奏。公 司为追求高质量发展，主动优化客户与订单结构，战略性收缩了部分低毛利、竞争激烈的项目，对公司 业绩造成一定影响。另外，部分产品受客户需求结构性变化、备货策略及材料涨价等因素影响导致其可 变现净值低于账面价值，公司根据《企业会计准则第8号一一资产减值》的相关要求，对部分存货计提 减值准备，亦对公司本期业绩产生影响。 为应对上述影响，公司将持续加大市场开拓力度，一方面，积 ...

格隆汇1月27日｜昂瑞微公告，预计2025年年度归母净利润亏损1.1亿元—1.5亿元。2025年，部分客户基 于因自身终端销售预期及供应链情况调整了采购节奏，阶段性放缓了提货节奏。公司为追求高质量发 展，主动优化客户与订单结构，战略性收缩了部分低毛利、竞争激烈的项目，对公司业绩造成一定影 响。另外，部分产品受客户需求结构性变化、备货策略及材料涨价等因素影响导致其可变现净值低于账 面价值，公司根据《企业会计准则第8号——资产减值》的相关要求，对部分存货计提减值准备，亦对 公司本期业绩产生影响。 ...

Core Viewpoint - JiuLiang Co., Ltd. (300808.SZ) expects a loss of 66 million to 86 million yuan in 2025, with a non-recurring loss of 60 million to 78 million yuan, indicating a further deterioration in performance compared to the previous year [1] Group 1: Financial Performance - The company reported a loss during the reporting period, which has increased compared to the same period last year due to a decline in sales scale and a reduction in gross profit, negatively impacting net profit [1] - The anticipated losses for 2025 are attributed to several factors, including the need to return government subsidies due to changes in the company's registered address to align with regional strategic upgrades [1] - The company’s asset, the BaiSha Industrial Park, will incur depreciation after being transferred to a subsidiary, which will also affect net profit due to increased fixed asset depreciation and tax burden [1] Group 2: Strategic Adjustments - The company is experiencing increased management expenses due to talent acquisition and industrial upgrades, which further impacts net profit [1] - In response to the anticipated losses, the company is actively adjusting its business strategy and exploring new profit growth points to enhance core competitiveness and improve performance for investors [1]

Core Viewpoint - *ST Lvkang (002868.SZ) expects a net profit attributable to shareholders of the listed company to be between -140 million and -125 million yuan for 2025, with operating revenue projected to be between 500 million and 515 million yuan [1] Group 1: Financial Performance - The main reason for the company's performance change this year is the expected positive equity attributable to shareholders due to the divestiture of the severely loss-making photovoltaic film business in 2025, which will no longer be included in the consolidated financial statements [1] - The net profit attributable to shareholders is still expected to be a loss primarily due to the losses incurred by the photovoltaic film business before its divestiture, which accounted for over 90% of the losses [1] - The veterinary medicine business has seen revenue growth this year, mainly driven by higher-margin products and an optimized product structure, resulting in an overall improvement in gross margin compared to 2024 [1]

国民技术公告，预计2025年归属于上市公司股东的净利润为亏损9800万元至1.20亿元，上年同期亏损 23534.24万元。业绩变动主要原因：集成电路关键元器件及负极材料业务收入与毛利同比增长；上年同 期子公司终止股权激励一次性确认股份支付费用5865.52万元；资产减值损失同比减少约5200万元；预 计本报告期非经常性损益金额约为2300万元，主要是取得政府补助。 （文章来源：第一财经） ...

南财智讯1月27日电，天威视讯发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为亏 损16,000.00万元—22,000.00万元，预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为 亏损18,400.00万元—24,400.00万元；公司预计2025年利润总额、归属于上市公司股东的净利润、归属于 上市公司股东的扣除非经常性损益的净利润亏损主要原因：一是受市场环境变化、行业竞争加剧等因素 影响，广深及周边地区通用数据中心机柜租赁价格持续下行，虽然公司市场团队多方努力，但深汕威视 数据中心（一期）以及南山、龙华数据中心销售仍未达预期，根据《企业会计准则第8号一资产减 值》，基于谨慎性原则，公司对上述三个数据中心资产拟计提减值，最终资产减值准备实际计提金额以 评估机构的评估报告及会计师事务所审计数据为准；二是受用户消费习惯、市场变化等影响，公司传统 有线电视、宽带业务收入等出现下降；三是对合同资产计提减值准备，以及与收益相关的政府补助较上 年同期减少。 ...

格隆汇1月27日｜正和生态公告，预计2025年年度实现归属于母公司所有者的净利润为-14,000万元 到-12,000万元；预计2025年年度实现归属于母公司所有者的扣除非经常性损益后的净利润为-14,000万 元到-12,000万元；预计2024年年度扣除与主营业务无关的业务收入和不具备商业实质的收入后的营业 收入为35,000万元到40,000万元。 ...

Core Viewpoint - Bluefeng Biochemical (002513.SZ) expects a net profit loss attributable to shareholders of the listed company between 230 million and 150 million yuan for the year 2025, with a similar range for net profit after deducting non-recurring gains and losses [1] Group 1: Performance Forecast - The company anticipates a net profit loss of 230 million to 150 million yuan for the year 2025 [1] - The expected loss after deducting non-recurring gains and losses is also projected to be between 230 million and 150 million yuan [1] Group 2: Reasons for Performance Changes - The company and its subsidiaries conducted a comprehensive review of various assets at the end of the reporting period, leading to the recognition of asset impairment provisions due to signs of impairment, which reduced the net profit attributable to shareholders by approximately 64.16 million yuan [1] - The agricultural chemical segment continues to incur losses due to a significant increase in raw material prices while the sales prices of main products have been declining [1] - Although the new energy segment has reduced production costs through technological upgrades, it still faces low product prices due to industry competition, resulting in a significant decrease in the loss margin year-on-year, but the profitability has not met expectations [1]

蓝丰生化公告称，2025年1月1日至12月31日，公司预计归属于上市公司股东的净利润亏损1.5亿-2.3亿 元，上年同期亏损2.53亿元；扣非净利润亏损1.5亿-2.3亿元，上年同期亏损2.32亿元；基本每股收益亏 损0.61元/股-0.40元/股，上年同期亏损0.68元/股。业绩变动主要因计提资产减值准备及农化、新能源板 块表现不佳，盈利未达预期。 ...